Detection of anti-infliximab antibodies is impacted by antibody titer, infliximab level and IgG4 antibodies: a systematic comparison of three different assays

Detection of anti-infliximab antibodies is impacted by antibody titer, infliximab level and IgG4 antibodies: a systematic comparison of three different assays

Background: There is scant information on the accuracy of different assays used to measure anti-infliximab antibodies (ADAs), especially in the presence of detectable infliximab (IFX). We thus aimed to evaluate and compare three different assays for the detection of IFX and ADAs and to clarify the i...

Full description

Bibliographic Details
Main Authors:	Joana Afonso, Susana Lopes, Raquel Gonçalves, Paulo Caldeira, Paula Lago, Helena Tavares de Sousa, Jaime Ramos, Ana Rita Gonçalves, Paula Ministro, Isadora Rosa, Ana Isabel Vieira, Rosa Coelho, Patrícia Tavares, João Soares, Ana Lúcia Sousa, Diana Carvalho, Paula Sousa, João Pereira da Silva, Tânia Meira, Filipa Silva Ferreira, Cláudia Camila Dias, Yehuda Chowers, Shomron Ben-Horin, Fernando Magro
Format:	Article
Language:	English
Published:	SAGE Publishing 2016-11-01
Series:	Therapeutic Advances in Gastroenterology
Online Access:	https://doi.org/10.1177/1756283X16658223

Similar Items

Calprotectin and the Magnitude of Antibodies to Infliximab in Clinically-stable Ulcerative Colitis Patients are More Relevant Than Infliximab Trough Levels and Pharmacokinetics for Therapeutic Escalation
by: Fernando Magro, et al.
Published: (2017-07-01)

Rapid test detection of anti-infliximab antibodies: performance comparison with three different immunoassays
by: Cátia Rocha, et al.
Published: (2020-11-01)

Clinical performance of an infliximab rapid quantification assay
by: Fernando Magro, et al.
Published: (2017-09-01)

Serum Levels of Infliximab and Anti-Infliximab Antibodies in Brazilian Patients with Crohn’s Disease
by: Luis Eduardo Miani Gomes, et al.
Published: (2019-04-01)

Early infliximab antibody testing does not prevent infusion reactions when reinitiating infliximab
by: Joseph D. Feuerstein
Published: (2016-08-01)

Improving anti-drug antibody assay performance in Gyrolab for therapeutic recombinant antibody Infliximab
by: Cecilia, Bill
Published: (2014)

Low Dose Infliximab for Prevention of Postoperative Recurrence of Crohn's Disease: Long Term Follow-Up and Impact of Infliximab Trough Levels and Antibodies to Infliximab.
by: Dario Sorrentino, et al.
Published: (2015-01-01)

Anti-infliximab antibodies and clinical response in noninfectious uveitis and scleritis patients treated with infliximab: A retrospective review
by: Cox, J.T, et al.
Published: (2022)

Low infliximab serum trough levels and anti-infliximab antibodies are prevalent in rheumatoid arthritis patients treated with infliximab in daily clinical practice: results of an observational cohort study
by: van der Maas Aatke, et al.
Published: (2012-09-01)

Clinical role, optimal timing and frequency of serum infliximab and anti-infliximab antibody level measurements in patients with inflammatory bowel disease.
by: Renáta Bor, et al.
Published: (2017-01-01)

Pneumococcal Antibody Titers
by: Pamella F. Abghari MD, et al.
Published: (2017-02-01)

Uso de infliximabe na policondrite recidivante Infliximab in relapsing polychondritis
by: Ana Paula Soares de Barros, et al.
Published: (2010-04-01)

Association of IgG1 Antibody Clearance with FcγRIIA Polymorphism and Platelet Count in Infliximab-Treated Patients
by: Gilles Thibault, et al.
Published: (2021-06-01)

Presence of anti-nuclear antibodies is a risk factor for the appearance of anti-drug antibodies during infliximab or adalimumab therapy in patients with rheumatoid arthritis.
by: Ayano Mori, et al.
Published: (2020-01-01)

Correlation of antinuclear antibody and anti-double-stranded DNA antibody with clinical response to infliximab in patients with rheumatoid arthritis: a retrospective clinical study
by: Yukawa, Naoichiro
Published: (2012)

Hidradenite supurativa tratada com infliximabe Hidradenitis suppurativa treated with infliximab
by: Daniel Lago Obadia, et al.
Published: (2009-12-01)

Tratamento com infliximabe da doença de Behçet ativa Therapy with infliximab in active Behçet's disease
by: Alexandre Wagner Silva de Souza, et al.
Published: (2005-04-01)

Switch from Infliximab to Infliximab-dyyb for Rheumatology Indications
by: Alexi Spoto, et al.
Published: (2021-05-01)

Drug Tolerant Anti-drug Antibody Assay for Infliximab Treatment in Clinical Practice Identifies Positive Cases Earlier
by: Nastya Kharlamova, et al.
Published: (2020-07-01)

Anti-Drug Antibodies in Patients with Inflammatory Bowel Diseases Treated with Biosimilar Infliximab: A Prospective Cohort Study
by: Anna Pękala, et al.
Published: (2021-06-01)

Tuberculose esplênica durante tratamento de psoríase com infliximabe Splenic tuberculosis during psoriasis treatment with infliximab
by: Gleyce Tavares de Melo Fortaleza, et al.
Published: (2009-08-01)

Chorea Associated with High Titers of Antiphospholipid Antibodies in the Absence of Antiphospholipid Antibody Syndrome
by: Damoun Safarpour, et al.
Published: (2015-02-01)

Therapeutic Immunoglobulin Selected For High Antibody Titer to RSV Also Contains High Antibody Titers to Other Respiratory Viruses
by: Jordan eOrange
Published: (2015-08-01)

Infusion reaction to infliximab biosimilar after transitioning from infliximab
by: Reem Kashlan, MPH, et al.
Published: (2021-02-01)

Dynamics of serum concentrations of antibodies to infliximab: a new approach for predicting secondary loss of response in inflammatory bowel diseases
by: Melina K. Grasmeier, et al.
Published: (2021-08-01)

A generic sample preparation approach for LC–MS/MS bioanalysis of therapeutic monoclonal antibodies in serum applied to Infliximab
by: Anne J. Kleinnijenhuis, et al.
Published: (2015-01-01)

Surface plasmon resonance unveils important pitfalls of enzyme-linked immunoassay for the detection of anti-infliximab antibodies in patients’ sera
by: Marten Beeg, et al.
Published: (2021-07-01)

Antibody titers in Group O platelet donors
by: Anita Amar Tendulkar, et al.
Published: (2017-01-01)

Extensive Refractory Perineal Pyoderma Gangrenosum Treated with Infliximab, Fecal Diversion, and Negative-Pressure Wound Therapy
by: Mafalda Sousa, et al.
Published: (2019-09-01)

Cutaneous vasculitis and granulomatous hepatitis as paradoxical adverse events of Infliximab
by: DIogo Esperança Almeida, et al.
Published: (2020-04-01)

Switching and Discontinuation Patterns Among Patients Stable on Originator Infliximab Who Switched to an Infliximab Biosimilar or Remained on Originator Infliximab
by: Fitzgerald T, et al.
Published: (2021-01-01)

Infliximab in Crohn's disease Infliximab en la enfermedad de Crohn
by: L. Rodrigo Sáez
Published: (2004-06-01)

Infliximab and biosimilar infliximab in psoriasis: efficacy, loss of efficacy, and adverse events
by: Subedi S, et al.
Published: (2019-07-01)

Analysis of the tensile strength on the healing of the abdominal wall of rats treated with infliximab Análise da força tênsil na cicatrização da parede abdominal de ratos tratados com infliximabe
by: João Vieira Lopes, et al.
Published: (2008-10-01)

Established in vitro detection system on the antibody neutralization titer and influence of the different immunized strategies on the antibody titer to Trimeresurus mucrosquamatus snake venom
by: Hsu-Wen Yen, et al.
Published: (2010)

Quantification of neutralizing anti-drug antibodies and their neutralizing capacity using competitive displacement and tandem mass spectrometry: Infliximab as proof of principle
by: Mohsin El Amrani, et al.
Published: (2019-04-01)

Antinuclear, anti-dsDNA and anti-ENA antibodies in patients affected with rheumatoid arthritis or ankylosing spondylitis during treatement with infliximab
by: L. Punzi, et al.
Published: (2011-09-01)

Using simple models to describe the kinetics of growth, glucose consumption, and monoclonal antibody formation in naive and infliximab producer CHO cells
by: López-Meza, Julián, et al.
Published: (2016)

Infliximab in Crohn's disease
by: L. Rodrigo Sáez

Infliximab in ulcerative colitis
by: Avi Levin, et al.
Published: (2008-09-01)